A Chinese pharmaceutical company expects to hire up to 500 employees for the first phase of its new campus in northern ...

NAMSA recently announced plans to acquire WuXi AppTec’s medical device testing operations in the U.S. As part of the ...

WuXi AppTec is parting ways with its U.S. medical device testing business, selling its two stateside locations to the Ohio-based regulatory consulting firm NAMSA. | The deal includes facilities in ...

WuXi AppTec, the Shanghai-based biotech giant, has sold its South Philly-based WuXi Advanced Therapies contract manufacturing unit to New York-based Altaris LLC, easing worries that federal limits on ...

The companies have committed to working in close collaboration to ensure a smooth transition for employees and customers.

China's WuXi Biologics said on Monday it will sell its vaccine facility in Ireland to U.S. drugmaker Merck & Co for about $500 million. The Financial Times had reported in October that WuXi and WuXi ...

WuXi AppTec said Tuesday it has entered into a definitive agreement to sell its WuXi Advanced Therapies operations at the Philadelphia Navy Yard to New York health care investment firm Altaris.

Shanghai-based WuXi AppTec focuses on drug discovery, development, and manufacturing. Founded in 2001 as WuXi PharmaTech, the company rebranded to its current name after acquiring the U.S.-based ...